Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1318131rdf:typepubmed:Citationlld:pubmed
pubmed-article:1318131lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0017066lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0070895lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0238097lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0023866lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0677908lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0085973lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0007320lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:1318131lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:1318131pubmed:issue5lld:pubmed
pubmed-article:1318131pubmed:dateCreated1992-7-16lld:pubmed
pubmed-article:1318131pubmed:abstractTextCytomegalovirus (CMV) causes life-threatening disseminated infections and in particular vision-threatening infections of the retina in patients with the acquired immunodeficiency syndrome. Ganciclovir currently represents the most frequently used therapy for CMV retinitis. However, cases of ganciclovir-resistant CMV strains have been described, in which foscarnet seems to be an effective alternative. Both drugs have serious toxicities, and relapses frequently occur during maintenance therapy. In a patient with CMV encephalitis, we administered a 3-week combination ganciclovir/foscarnet induction therapy (ganciclovir 5 mg/kg every 12 h; foscarnet 60 mg/kg every 8 h), followed by an alternating maintenance administration of both drugs every other day (ganciclovir 5 mg/kg, foscarnet 120 mg/kg) to reduce toxicity and resistance. This regimen was tolerated well and seemed to be more effective than ganciclovir alone in a patient with CMV encephalitis.lld:pubmed
pubmed-article:1318131pubmed:languageenglld:pubmed
pubmed-article:1318131pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1318131pubmed:citationSubsetIMlld:pubmed
pubmed-article:1318131pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1318131pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1318131pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1318131pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1318131pubmed:statusMEDLINElld:pubmed
pubmed-article:1318131pubmed:monthMaylld:pubmed
pubmed-article:1318131pubmed:issn0941-0198lld:pubmed
pubmed-article:1318131pubmed:authorpubmed-author:TimmUUlld:pubmed
pubmed-article:1318131pubmed:authorpubmed-author:PetersMMlld:pubmed
pubmed-article:1318131pubmed:authorpubmed-author:PohleH DHDlld:pubmed
pubmed-article:1318131pubmed:authorpubmed-author:SUClld:pubmed
pubmed-article:1318131pubmed:authorpubmed-author:SchürmannDDlld:pubmed
pubmed-article:1318131pubmed:issnTypePrintlld:pubmed
pubmed-article:1318131pubmed:volume70lld:pubmed
pubmed-article:1318131pubmed:ownerNLMlld:pubmed
pubmed-article:1318131pubmed:authorsCompleteYlld:pubmed
pubmed-article:1318131pubmed:pagination456-8lld:pubmed
pubmed-article:1318131pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:meshHeadingpubmed-meshheading:1318131-...lld:pubmed
pubmed-article:1318131pubmed:year1992lld:pubmed
pubmed-article:1318131pubmed:articleTitleCombined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.lld:pubmed
pubmed-article:1318131pubmed:affiliationII. Medizinische Klinik, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin.lld:pubmed
pubmed-article:1318131pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1318131pubmed:publicationTypeReviewlld:pubmed
pubmed-article:1318131pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1318131lld:pubmed